Devonian Health Group stock analysis
The latest update is out from Devonian Health Group ( ($TSE:GSD) ). Devonian Health Group has received authorization from Health Canada to launch a 150-patient, randomized, double-blind, multicenter clinical trial
Devonian Health Group ( ($TSE:GSD) ) just unveiled an update. Devonian Health Group Inc., a Quebec-based clinical-stage pharmaceutical company, develops prescription drugs for fibroinflammatory autoimmune diseases such as atopic dermatitis,
An announcement from Devonian Health Group ( ($TSE:GSD) ) is now available. Devonian Health Group has strengthened the manufacturing platform for its lead botanical drug candidate Thykamine™ by integrating independently
The latest update is out from Devonian Health Group ( ($TSE:GSD) ). Devonian Health Group Inc., a Quebec-based clinical-stage pharmaceutical company, develops prescription drugs for fibroinflammatory autoimmune diseases such as
Devonian Health Group ( ($TSE:GSD) ) has provided an update. Devonian Health Group reported positive preclinical results showing that its lead candidate Thykamine reduced key markers of fibrosis and inflammation
Devonian Health Group ( ($TSE:GSD) ) has shared an update. Devonian Health Group has strengthened the intellectual property and manufacturing framework for its lead drug candidate Thykamine by formally integrating
Devonian Health Group ( ($TSE:GSD) ) has issued an update. Devonian Health Group reported compelling preclinical results showing its lead drug candidate Thykamine™ achieved statistically significant antifibrotic and anti-inflammatory effects
Devonian Health Group, Inc. is a clinical-stage pharmaceutical company. The firm is engaged in the development of drugs for a range of autoimmune and fibroinflammatory conditions, using novel therapeutic approaches to address unmet medical needs. It offers therapeutic and cosmeceutical products. Its drug candidate, Thykamine product is issued from Devonian’s SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The company was founded by Andre P. Boulet on March 27, 2015 and is headquartered in Montmagny, Canada.
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 6 | 10 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 4 | 0 | 8 |
